We are live on ! Find out more
CALA

Calithera Biosciences, Inc

Delisted

CALA was delisted on the 1st of February, 2023.

54 hedge funds and large institutions have $17.9M invested in Calithera Biosciences, Inc in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,533% more call options, than puts

Call options by funds: $139K | Put options by funds: $3K

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

2% less funds holding

Funds holding: 5554 (-1)

34% less capital invested

Capital invested by funds: $27M → $17.9M (-$9.1M)

Holders
54
Holders Change
-1
Holders Change %
-1.82%
% of All Funds
0.85%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
12
Reduced
12
Closed
14
Calls
$139K
Puts
$3K
Net Calls
+$136K
Net Calls Change
-$45K
Name Holding Trade Value Shares
Change
Change in
Stake
Primecap Management
1
Primecap Management
California
$4.34M
BI
2
BVF Inc
California
$3.75M +$941K +92,129 +25%
Citadel Advisors
3
Citadel Advisors
Florida
$1.61M +$240K +23,481 +13%
TCMG
4
TSP Capital Management Group
New Jersey
$1.06M
Vanguard Group
5
Vanguard Group
Pennsylvania
$863K -$370K -36,241 -25%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$797K +$61.4K +6,010 +6%
BlackRock
7
BlackRock
New York
$777K +$3.71K +363 +0.4%
Renaissance Technologies
8
Renaissance Technologies
New York
$749K +$253K +24,805 +37%
Two Sigma Advisers
9
Two Sigma Advisers
New York
$502K +$21.4K +2,095 +3%
AAA
10
Affinity Asset Advisors
New York
$404K +$511K +50,000 New
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$404K +$511K +50,000 New
Two Sigma Investments
12
Two Sigma Investments
New York
$342K -$70.4K -6,887 -14%
EAM
13
Empery Asset Management
New York
$313K +$396K +38,796 New
Assenagon Asset Management
14
Assenagon Asset Management
Luxembourg
$304K
Millennium Management
15
Millennium Management
New York
$260K +$62K +6,065 +23%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$238K +$6.55K +641 +2%
JP Morgan Chase
17
JP Morgan Chase
New York
$221K
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$97K -$653K -63,951 -84%
State Street
19
State Street
Massachusetts
$87K
ACM
20
Altium Capital Management
New York
$82K +$103K +10,114 New
Truist Financial
21
Truist Financial
North Carolina
$81K +$102K +10,000 New
BCM
22
Bridgeway Capital Management
Texas
$74K
Northern Trust
23
Northern Trust
Illinois
$61K -$1.18K -115 -2%
Franklin Resources
24
Franklin Resources
California
$54K
FSA
25
Franklin Street Advisors
North Carolina
$54K

CALA Hedge Fund Activity: Q1 2022 in Review

54 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q1 2022, worth a combined $17.9M — down 34% from $27M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of CALA and 13 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 12 added.

The largest buyer was BVF Inc, adding an estimated $941K. The largest seller was D.E. Shaw & Co, cutting an estimated $653K.

  • 54 institutional investors held Calithera Biosciences, Inc (CALA) as of Q1 2022, down from 55 in Q4 2021.
  • Funds reported $17.9M of Calithera Biosciences, Inc stock for Q1 2022, down 34% quarter-over-quarter.
  • 13 funds opened new Calithera Biosciences, Inc positions in Q1 2022 and 14 closed out, a net change of -1 holder.
  • The largest Calithera Biosciences, Inc buyer in Q1 2022 was BVF Inc, an estimated $941K added.
  • The largest Calithera Biosciences, Inc seller in Q1 2022 was D.E. Shaw & Co, an estimated $653K sold.

Based on aggregated 13F filings for Q1 2022.